Sigma Planning Corp’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.94M | Sell |
15,203
-5,285
| -26% | -$660K | 0.05% | 340 |
|
|
2025
Q4 | $2.5M | Buy |
20,488
+18,479
| +920% | +$2.12M | 0.07% | 286 |
|
|
2025
Q3 | $201K | Buy |
+2,009
| New | +$181K | 0.01% | 1216 |
|
|
2025
Q1 | – | Sell |
-5,000
| Closed | -$450K | – | 1298 |
|
|
2024
Q4 | $450K | Sell |
5,000
-6,924
| -58% | -$671K | 0.01% | 776 |
|
|
2024
Q3 | $1.18M | Buy |
11,924
+3,781
| +46% | +$371K | 0.04% | 454 |
|
|
2024
Q2 | $755K | Sell |
8,143
-14,425
| -64% | -$1.29M | 0.02% | 566 |
|
|
2024
Q1 | $2.14M | Buy |
22,568
+17,610
| +355% | +$1.63M | 0.07% | 293 |
|
|
2023
Q4 | $443K | Sell |
4,958
-5,312
| -52% | -$394K | 0.03% | 490 |
|
|
2023
Q3 | $750K | Sell |
10,270
-463
| -4% | -$37K | 0.03% | 557 |
|
|
2023
Q2 | $893K | Sell |
10,733
-1,656
| -13% | -$138K | 0.03% | 505 |
|
|
2023
Q1 | $944K | Sell |
12,389
-559
| -4% | -$46.4K | 0.03% | 533 |
|
|
2022
Q4 | $1.07M | Sell |
12,948
-576
| -4% | -$46.6K | 0.04% | 449 |
|
|
2022
Q3 | $1.07M | Sell |
13,524
-3,551
| -21% | -$299K | 0.04% | 434 |
|
|
2022
Q2 | $1.27M | Buy |
17,075
+1,939
| +13% | +$146K | 0.04% | 385 |
|
|
2022
Q1 | $1.36M | Buy |
15,136
+5,187
| +52% | +$479K | 0.04% | 425 |
|
|
2021
Q4 | $1.11M | Buy |
9,949
+858
| +9% | +$103K | 0.03% | 513 |
|
|
2021
Q3 | $1.14M | Sell |
9,091
-704
| -7% | -$90.7K | 0.03% | 496 |
|
|
2021
Q2 | $1.33M | Buy |
9,795
+1,952
| +25% | +$257K | 0.04% | 455 |
|
|
2021
Q1 | $1.06M | Sell |
7,843
-3,060
| -28% | -$458K | 0.03% | 479 |
|
|
2020
Q4 | $1.53M | Buy |
10,903
+3,143
| +41% | +$403K | 0.05% | 338 |
|
|
2020
Q3 | $865K | Sell |
7,760
-10,769
| -58% | -$1.21M | 0.03% | 441 |
|
|
2020
Q2 | $2.07M | Sell |
18,529
-1,354
| -7% | -$133K | 0.09% | 231 |
|
|
2020
Q1 | $1.54M | Buy |
19,883
+1,000
| +5% | +$88.5K | 0.09% | 228 |
|
|
2019
Q4 | $1.8M | Sell |
18,883
-2,643
| -12% | -$229K | 0.08% | 268 |
|
|
2019
Q3 | $1.64M | Buy |
21,526
+45
| +0.2% | +$3.74K | 0.08% | 263 |
|
|
2019
Q2 | $1.88M | Buy |
21,481
+4,350
| +25% | +$371K | 0.1% | 222 |
|
|
2019
Q1 | $1.55M | Buy |
17,131
+9,231
| +117% | +$785K | 0.09% | 239 |
|
|
2018
Q4 | $567K | Sell |
7,900
-958
| -11% | -$77.2K | 0.04% | 397 |
|
|
2018
Q3 | $849K | Sell |
8,858
-325
| -4% | -$31.5K | 0.05% | 336 |
|
|
2018
Q2 | $874K | Sell |
9,183
-486
| -5% | -$44.7K | 0.06% | 317 |
|
|
2018
Q1 | $848K | Sell |
9,669
-312
| -3% | -$28.5K | 0.06% | 300 |
|
|
2017
Q4 | $847K | Buy |
9,981
+66
| +0.7% | +$5.53K | 0.07% | 294 |
|
|
2017
Q3 | $858K | Buy |
9,915
+867
| +10% | +$69.5K | 0.07% | 284 |
|
|
2017
Q2 | $698K | Buy |
9,048
+1,879
| +26% | +$133K | 0.07% | 325 |
|
|
2017
Q1 | $497K | Sell |
7,169
-2,246
| -24% | -$151K | 0.05% | 394 |
|
|
2016
Q4 | $557K | Sell |
9,415
-3,192
| -25% | -$197K | 0.06% | 323 |
|
|
2016
Q3 | $836K | Buy |
12,607
+461
| +4% | +$28.5K | 0.1% | 228 |
|
|
2016
Q2 | $657K | Buy |
12,146
+5,317
| +78% | +$291K | 0.09% | 263 |
|
|
2016
Q1 | $353K | Sell |
6,829
-19
| -0.3% | -$987 | 0.05% | 405 |
|
|
2015
Q4 | $481K | Sell |
6,848
-211
| -3% | -$14.4K | 0.07% | 324 |
|
|
2015
Q3 | $439K | Sell |
7,059
-126
| -2% | -$9.93K | 0.07% | 333 |
|
|
2015
Q2 | $604K | Buy |
7,185
+69
| +1% | +$5.37K | 0.08% | 281 |
|
|
2015
Q1 | $535K | Buy |
7,116
+1,653
| +30% | +$115K | 0.07% | 325 |
|
|
2014
Q4 | $340K | Buy |
+5,463
| New | +$311K | 0.04% | 453 |
|
Other funds holding XBI
Sigma Planning Corp's XBI Position: Q1 2026 in Review
Sigma Planning Corp reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 26% in Q1 2026, selling an estimated $660K and leaving 15,203 shares worth $1.94M. The position accounts for 0.05% of the portfolio, ranked #340.
Sigma Planning Corp first reported a position in XBI in Q4 2014 and has held it in 44 quarters since. The position peaked at $2.5M in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Sigma Planning Corp held 15,203 shares of State Street SPDR S&P Biotech ETF worth $1.94M as of Q1 2026.
- Sigma Planning Corp sold 5,285 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $660K.
- State Street SPDR S&P Biotech ETF made up 0.05% of Sigma Planning Corp's portfolio in Q1 2026, its #340 holding.
- Sigma Planning Corp first reported a position in State Street SPDR S&P Biotech ETF in Q4 2014 and has held it in 44 quarters since.
- Sigma Planning Corp's State Street SPDR S&P Biotech ETF position peaked at $2.5M in Q4 2025.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.